Jon Napitupulu

MAIA Biotechnology will collaborate with BeiGene to evaluate THIO, MAIA’s telomere-targeting anticancer drug, in combination with BeiGene’s immune checkpoint...

The global retinal gene therapy market is projected to exceed US$110 million in revenue in 2024, driven by the...

BioSkryb Genomics launched ResolveSEQ MRD, a service that enhances the analysis of minimal residual disease (MRD) in hematological malignancies....

Tenvie Therapeutics launched with $200 million in funding to develop small molecule treatments for neurological diseases. The company acquired...

The sales of the top 20 drugs targeting molecular switches have exceeded $30 billion, highlighting the growing importance of...

Quanta Therapeutics announced advancements in its KRAS-directed drug candidates, including FDA IND clearance for QTX3544, a G12V-preferring multi-KRAS inhibitor,...

AerWave Medical completed its first-in-human feasibility study of a novel ultrasound lung denervation therapy for chronic obstructive pulmonary disease...

Bitterroot Bio announced positive Phase 1 results for BRB-002, a first-in-class immune-modulating protein therapy targeting CD47 for atherosclerotic cardiovascular...

Cassava Sciences announced a 33% workforce reduction, cost-cutting measures, and anticipated topline data release from its Phase 3 REFOCUS-ALZ...

Asher Biotherapeutics and AstraZeneca have partnered to evaluate etakafusp alfa (AB248), Asher Bio’s CD8+ T cell-targeted IL-2 immunotherapy, in...